Skip to content
akaturk Academic measurement
Sign in Sign up

OpenAlex topic

Radiopharmaceutical Chemistry and Applications

This page lists works and academicians tagged with an OpenAlex topic. It is not a YÖKSİS primary or secondary field.

OpenAlex 2,558 works 78 author topics

Works

2,558 works

  1. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial 2019
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

    BACKGROUND: In the interim analyses of the LATITUDE study, the addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) led to a significant improvement in overall survival and radiographic progression-free survival compared with placebos plus ADT in men with newly diagnosed high-risk meta…

  2. The mammary gland iodide transporter is expressed during lactation and in breast cancer 2000
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.5%

    No abstract yet.

  3. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer 2004
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.6%

    No abstract yet.

  4. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer 2004
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.6%

    No abstract yet.

  5. A randomized clinical trial of combination chemotherapy with and without low‐molecular‐weight heparin in small cell lung cancer 2004
    OpenAlex top 1% OpenAlex 99.6%

    No abstract yet.

  6. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT) 2019
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.8%

    No abstract yet.

  7. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions 2023
    SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

    Amivantamab has been approved for the treatment of patients with advanced non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertions who have had disease progression during or after platinum-based chemotherapy. Phase 1 data showed the safety and antitumor activity of amivantamab…

  8. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT) 2023
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

    Abstract Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with target-positive disease can easily be identified by PSMA PET imaging. Promising results with PSMA-targeted radiopharmaceutical therapy have already been obtained in earl…

  9. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT) 2023
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

    Abstract Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with target-positive disease can easily be identified by PSMA PET imaging. Promising results with PSMA-targeted radiopharmaceutical therapy have already been obtained in earl…

  10. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma 2024
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Bortezomib, lenalidomide, and dexamethasone (VRd) is a preferred first-line treatment option for patients with newly diagnosed multiple myeloma. Whether the addition of the anti-CD38 monoclonal antibody isatuximab to the VRd regimen would reduce the risk of disease progression or death among patients ineli…

  11. Pre therapeutic dosimetry of normal organs and tissues of 177Lu PSMA 617 prostate specific membrane antigen PSMA inhibitor in patients with castration resistant prostate cancer 2015
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.4%

    No abstract yet.

  12. A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements 2023
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

    Theranostics is the combination of two approaches—diagnostics and therapeutics—applied for decades in cancer imaging using radiopharmaceuticals or paired radiopharmaceuticals to image and selectively treat various cancers. The clinical use of theranostics has increased in recent years, with U.S. Food and Drug Administ…

Academicians

78 academicians